OBI Pharma, Inc.


Chairman: Dr. Michael Chang
Established Date: 2002/04/29 
Tel: 886-2-2655-8799 
Fax: 886-2-2655-7790 
Address: 1. Ste W1907, 19F, #3, Park St, Nankang Software Park, Taipei, 11503, Taiwan
2. 13F.-1, No.376, Sec. 4, Ren’ai Rd., Da’an Dist., Taipei City 10693, Taiwan
Website: http://www.obipharma.com/


 

Company Profile:

OBI Pharma, Inc., was founded in 2002. Its focus is on the "Unmet Medical Needs" in challenging diseases throughout the world, such as Cancer & Infectious Diseases. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics.

OBI's core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company uses its proprietary OPopS™ drug discovery platform to build a ground-breaking pipeline. OBI also works in close collaboration with prestigious research institutes, including Academia Sinica of Taiwan and the Memorial Sloane-Kettering Cancer Center of the US.

The company's flagship product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The on-going Phase 2/3 multinational, randomized controlled trial for metastatic breast cancer (ClinicalTrials.gov Identifier: NCT01516307) was launched in 2011. OBI is also devoted to developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.

New Drugs in Development:

New Drug

Indication

Strengths

Stage

Active Immunotherapy
OBI-822

Breast Cancer
Ovarian Cancer

Active immunotherapy is most versatile, safe and effective. New treatment for cancer currently under investigation for the treatment of metastatic breast cancer and ovarian cancer.

Phase II/III

Active Immunotherapy
OBI-833

Lung Cancer
Pancreatic Cancer

A new generation of active immunotherapy vaccine, It has low toxicity with great development potential and fewer side effects and high specificity.

IND(FDA)

Monoclonal Antibody for Cancer
OBI-888

14~16 Globo H Expression Cancers

Anti-Globo H monoclonal antibody can complement the active immunotherapy of cancer, especially for those undergoing radiation and /or chemo therapies patients.

Pre-Clinical

Botulinum Toxin Type A
OBI-858

Wrinkles and Muscle Spasticity

Widely used in cosmetic medicine, also used in the treatment of dystonia, strabismus, severe underarm sweating and migraine.

Pre-clinical

Glyco chip for cancer detection
OBI-868

Cancer Diagnostic

Can trace Globo H antibody only small Serum samples. Significantly enhance the sensitivity and accuracy of cancer early detection, postoperative follow up is another potential benefit for patients.

Pre-clinical